![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
24
PharmaCompass offers a list of Remifentanil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Remifentanil manufacturer or Remifentanil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Remifentanil manufacturer or Remifentanil supplier.
PharmaCompass also assists you with knowing the Remifentanil API Price utilized in the formulation of products. Remifentanil API Price is not always fixed or binding as the Remifentanil Price is obtained through a variety of data sources. The Remifentanil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Remifentanil Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Remifentanil Hydrochloride, including repackagers and relabelers. The FDA regulates Remifentanil Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Remifentanil Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Remifentanil Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Remifentanil Hydrochloride supplier is an individual or a company that provides Remifentanil Hydrochloride active pharmaceutical ingredient (API) or Remifentanil Hydrochloride finished formulations upon request. The Remifentanil Hydrochloride suppliers may include Remifentanil Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Remifentanil Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Remifentanil Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Remifentanil Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Remifentanil Hydrochloride DMFs exist exist since differing nations have different regulations, such as Remifentanil Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Remifentanil Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Remifentanil Hydrochloride USDMF includes data on Remifentanil Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Remifentanil Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Remifentanil Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Remifentanil Hydrochloride Drug Master File in Japan (Remifentanil Hydrochloride JDMF) empowers Remifentanil Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Remifentanil Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Remifentanil Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Remifentanil Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Remifentanil Hydrochloride Drug Master File in Korea (Remifentanil Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Remifentanil Hydrochloride. The MFDS reviews the Remifentanil Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Remifentanil Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Remifentanil Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Remifentanil Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Remifentanil Hydrochloride suppliers with KDMF on PharmaCompass.
A Remifentanil Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Remifentanil Hydrochloride Certificate of Suitability (COS). The purpose of a Remifentanil Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Remifentanil Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Remifentanil Hydrochloride to their clients by showing that a Remifentanil Hydrochloride CEP has been issued for it. The manufacturer submits a Remifentanil Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Remifentanil Hydrochloride CEP holder for the record. Additionally, the data presented in the Remifentanil Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Remifentanil Hydrochloride DMF.
A Remifentanil Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Remifentanil Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Remifentanil Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Remifentanil Hydrochloride written confirmation (Remifentanil Hydrochloride WC) is an official document issued by a regulatory agency to a Remifentanil Hydrochloride manufacturer, verifying that the manufacturing facility of a Remifentanil Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Remifentanil Hydrochloride APIs or Remifentanil Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Remifentanil Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Remifentanil Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Remifentanil Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Remifentanil Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Remifentanil Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Remifentanil Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Remifentanil Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Remifentanil Hydrochloride suppliers with NDC on PharmaCompass.
Remifentanil Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Remifentanil Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Remifentanil Hydrochloride GMP manufacturer or Remifentanil Hydrochloride GMP API supplier for your needs.
A Remifentanil Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Remifentanil Hydrochloride's compliance with Remifentanil Hydrochloride specifications and serves as a tool for batch-level quality control.
Remifentanil Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Remifentanil Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Remifentanil Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Remifentanil Hydrochloride EP), Remifentanil Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Remifentanil Hydrochloride USP).